AN2 Therapeutics, Inc. (ANTX) - 10-K Summary
Business Context and Reporting Period
Company: AN2 Therapeutics, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: AN2 is a clinical-stage biopharmaceutical company developing novel small-molecule therapeutics derived from a proprietary boron chemistry platform. The pipeline spans hematologic diseases, infectious diseases, and oncology. The company has no products approved for commercial sale and has incurred significant losses since inception.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(35.2) million | $(51.3) million |
| Operating Expenses | $38.1 million | $56.8 million |
| Research & Development (R&D) | $24.8 million | $40.5 million |
| General & Administrative (G&A) | $13.3 million | $14.1 million |
| Restructuring Charges | $0 | $2.2 million |
| Cash, Cash Equivalents & Investments | $60.0 million | $86.3 million |
| Accumulated Deficit | $(241.0) million | $(205.8) million |
| Cash Used in Operating Activities | $(29.8) million | $(49.3) million |
Note: The company has no debt obligations listed in the balance sheet. Liquidity is supported by cash and investments.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by 31% (from $51.3M to $35.2M), primarily driven by a 39% reduction in R&D expenses and the absence of restructuring charges in 2025 (compared to $2.2M in 2024).
- R&D Expense Shift: Clinical trial expenses dropped significantly by $12.8M due to the termination of the EBO-301 trial in August 2024. This was partially offset by a 139% increase in preclinical and research study expenses ($5.0M increase) as the company prioritized new research programs.
- Interest Income: Decreased by 46% to $2.9M due to lower investment balances and interest rates in 2025.
- Capital Raise: In March 2026 (subsequent to period end), the company completed a private placement raising $40.0 million in gross proceeds.
Guidance, Outlook, and Risks
Outlook and Pipeline Updates:
- Epetraborole (Polycythemia Vera): Plans to initiate a Phase 2 proof-of-concept study in India in Q3 2026. Data readouts expected starting Q4 2026.
- Epetraborole (M. abscessus): FDA cleared an Investigational New Drug (IND) application in December 2025 for a Phase 2 investigator-initiated trial. Enrollment expected in Q1 2026; topline results in late 2027.
- AN2-502998 (Chagas Disease): Phase 1 first-in-human trial commenced in August 2025. Initial data expected Q1 2026; Phase 2 initiation expected in 2026.
- Oncology: Plans to advance two preclinical candidates (targeting PI3Kα and ENPP1) into development in 2026.
Management Commentary:
- Management believes current cash resources ($60.0M as of Dec 31, 2025) plus the March 2026 financing will fund operations for at least 12 months following the filing date.
- The company continues to rely on non-dilutive funding (grants from NIAID, Gates Foundation) to support global health programs.
Risks and Contingencies:
- Material Weaknesses in Internal Controls: The company identified material weaknesses in internal control over financial reporting (control environment, period-end reporting, IT general controls) that remained unremediated as of December 31, 2025. This impacts the reliability of financial reporting.
- Clinical Trial Failure: The company discontinued development of epetraborole for treatment-refractory MAC lung disease in May 2025 after the Phase 3 portion of the EBO-301 study failed to meet its primary endpoint.
- Funding Requirements: The company expects to incur substantial additional losses and will require significant additional capital to advance its pipeline. Failure to raise capital could force delays or cessation of programs.
- Regulatory and IP Risks: Success depends on regulatory approvals and maintaining in-licensed patents (e.g., from Anacor/Pfizer), which expire as early as 2028.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $60.0M cash balance plus the $40.0M March 2026 raise against the projected burn rate for 2026-2027 clinical trials.
- Internal Controls: Review the remediation plan for the identified material weaknesses in internal controls over financial reporting to assess future reporting reliability.
- Clinical Timelines: Monitor the initiation dates for the Phase 2 PV trial (India) and the M. abscessus IIT, as delays could impact capital needs.
- Grant Funding: Confirm the status of non-dilutive funding from NIAID and the Gates Foundation, noting the $9.0M reduction in the NIAID contract ceiling in June 2025.
- Intellectual Property: Assess the expiration dates of in-licensed patents (June 2028) relative to the projected commercialization timeline.